US2012164176A1PendingUtilityA1

Rsv f protein compositions amd methods for making same

Assignee: SWANSON KURTPriority: Jul 15, 2009Filed: Jul 15, 2010Published: Jun 28, 2012
Est. expiryJul 15, 2029(~3 yrs left)· nominal 20-yr term from priority
A61P 37/04A61P 31/14A61P 11/00C07K 16/11C07K 2319/21A61K 2039/5256C07K 14/005C07K 2319/50A61K 2039/5252C07K 2317/76C12N 2760/18534A61K 2039/5258A61K 2039/55566A61K 39/12C07K 2319/73A61K 2039/55572A61K 2039/55505A61K 2039/53A61K 39/155C12N 2760/18522A61K 2039/55561C12N 2770/36143A61K 2039/55555C07K 2319/00A61K 39/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

Claims

exact text as granted — not AI-modified
1 - 98 . (canceled) 
     
     
         99 . An immunogenic composition comprising a population of soluble respiratory syncytial virus F (RSV F) polypeptides that are in the form of monomers, trimers, or a combination of monomers and trimers. 
     
     
         100 . The immunogenic composition of  claim 99 , wherein the timers are monodispersed trimers. 
     
     
         101 . The immunogenic composition of  claim 99 , wherein the RSV F polypeptides are in the form of a combination of monomers and trimers. 
     
     
         102 . The immunogenic composition of  claim 101 , wherein the monomers and trimers are in dynamic equilibrium. 
     
     
         103 . The immunogenic composition of  claim 99 , wherein the soluble RSV F polypeptides are ectodomain polypeptides. 
     
     
         104 . The immunogenic composition of  claim 103 , wherein the soluble RSV F polypeptides are uncleaved. 
     
     
         105 . The immunogenic composition of  claim 103 , wherein the soluble RSV F polypeptides are cleaved. 
     
     
         106 . The immunogenic composition of  claim 99 , further comprising an adjuvant. 
     
     
         107 . A method of inducing an immune response in a subject to RSV F comprising administering said subject an immunogenic composition of  claim 99 .

Join the waitlist — get patent alerts

Track US2012164176A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.